Wall Street's Top Analyst Ratings: Cummins Upgraded

Here are the latest influential analyst rating changes that investors should monitor today.

**Key Upgrades** Raymond James upgraded Cummins (CMI) from "Market Perform" to "Outperform" with a $585 price target. The firm noted a "significant positive shift" in expectations for H2 2026, despite near-term caution due to the freight sector’s prolonged downturn, based on discussions with U.S. truck dealers.

Loop Capital raised Ollie’s Bargain Outlet (OLLI) from "Hold" to "Buy," lifting its target from $130 to $135, citing underestimated same-store sales growth potential for FY2026.

Banco Bradesco turned bullish on Mexican airline Volaris (VLRS), upgrading it from "Neutral" to "Outperform" with a $12 target.

**Key Downgrades** Citigroup downgraded Amicus Therapeutics (FOLD) from "Buy" to "Neutral," slashing its target from $17 to $14.50, following BioMarin’s $48/share acquisition offer. Citi sees low odds of competing bids.

Raymond James cut Sealed Air (SEE) two notches from "Strong Buy" to "Market Perform" without a target, as the CD&R buyout’s "go-shop" period expired on Dec. 16, reducing chances of higher bids.

William Blair and Oppenheimer both downgraded Clearwater Analytics (CWAN) to "Market Perform" (no target) after its $24.55/share cash buyout deal.

Janney Montgomery Scott downgraded Heritage Commerce (HTBK) to "Neutral" ($14 fair value) post its acquisition announcement by CVB Financial (CVBF).

**Initiation Coverage** Wells Fargo initiated Arcellx (ACLX) at "Overweight" ($100 target), calling its immune-cell therapy a potential "cornerstone" for myeloma treatment.

Jefferies started BlackSky (BKSY) at "Buy" ($23 target), praising its satellite imaging capabilities and forecasting 25% annual revenue growth post-2026 constellation upgrades, with sales doubling to $211M by 2028.

BTIG initiated Invivyd (IVVD) at "Buy" ($10 target), citing its proven antibody development track record.

Jefferies also initiated Relmada Therapeutics (RLMD) at "Buy" ($9 target), highlighting its 2025 pivot from failed CNS drugs to oncology/neuroscience pipelines.

Harbor Research rated MasterCraft (MCFT) "Neutral" (no target), acknowledging U.S. consumer strength but flagging intense competition in wakeboard and pontoon boat segments.